Skip to main content
LEAP THERAPEUTICS, INC. logo

LEAP THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · LPTX ISIN · US52187K2006 LEI · 549300T31SMMJ2DDLI13 US Manufacturing
Open in API
Filings indexed 584 across all filing types
Latest filing 2023-11-13 Earnings Release
Country US United States of America
Listing US LPTX

About LEAP THERAPEUTICS, INC.

https://www.leaptx.com/

Leap Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted and immuno-oncology therapeutics for cancer. Its most advanced clinical candidate, DKN-01 (sirexatamab), is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein, being developed for patients with esophagogastric, gynecologic, and colorectal cancers. The company's pipeline also includes FL-301, a monoclonal antibody targeting Claudin18.2 for gastric and pancreatic cancer, and FL-501, a preclinical antibody targeting the growth and differentiation factor 15 (GDF-15) protein.

Recent filings

Filing Released Lang Actions
FORM 8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated November 13, 2023, reporting the financial results for the quarter ended September 30, 2023. It includes a press release as an exhibit announcing the quarterly financial results. The text explicitly states it is a Current Report on Form 8-K, which is used for reporting significant events including earnings announcements. The document is relatively short (4305 characters) and primarily serves as an announcement of quarterly financial results rather than a full detailed report. Therefore, it fits the definition of an Earnings Release (ER), which is the initial announcement of quarterly financial results with key highlights only.
2023-11-13 English
10-Q
Interim / Quarterly Report Q3 2023
2023-11-13 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated September 13, 2023, by Leap Therapeutics, Inc. It announces that the company has posted an updated corporate presentation on its website and includes the presentation as Exhibit 99.1. The text does not contain detailed financial statements or analysis but rather serves as a notification of the availability of the presentation. The document length is 3504 characters, which is relatively short and consistent with an announcement rather than a full report. According to the classification rules, announcements of presentations or reports that are short and refer to materials posted elsewhere should be classified as Regulatory Filings (RNS) rather than Investor Presentation (IP) or other report types. Therefore, the appropriate classification is Regulatory Filings (RNS).
2023-09-13 English
FORM S-8
Regulatory Filings Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC, which is used to register securities to be offered under employee benefit plans such as equity incentive plans. The text includes details about the amendment to the equity incentive plan, the number of shares registered, incorporation by reference of prior filings, and signatures of company officers. It is not a financial report, earnings release, or management discussion, but a regulatory filing related to securities registration. Therefore, it fits best under the category of Regulatory Filings (RNS). The document length and content confirm it is not a brief announcement or a report publication announcement.
2023-08-30 English
OWNERSHIP DOCUMENT
Director's Dealing
2023-08-25 English
OWNERSHIP DOCUMENT
Director's Dealing
2023-08-25 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.